INVESTORS & MEDIA

Press Releases


Press Releases

December 4, 2020
Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS) PBCAR0191 Demonstrated Longest Durability of Response to 11 months in B-ALL PBCAR0191 with Enhanced...
October 14, 2020
DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS ® genome editing platform, today announced that Alex Kelly has been appointed to the...
Displaying 1 - 10 of 30